Interleukin-6 in CLL: accelerator or brake?
In this issue of Blood, Li et al provide insight into the interactions between immunoreceptor signals in a human cancer microenvironment presenting a novel mechanism by which microenvironment-produced interleukin (IL)-6 acts as a tumor suppressor in chronic lymphocytic leukemia (CLL) by inhibiting toll-like receptor (TLR) signaling.